ArticleLupus science & medicine2026
Long-term outcomes of hydroxychloroquine dose reduction in Puerto Ricans with systemic lupus erythematosus: 6-year follow-up.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveTo reduce the risk of hydroxychloroquine (HCQ)-induced retinopathy, the American Academy of Ophthalmology recommends a maximum HCQ dose of ≤5.0 mg/kg/day. Previously, we reported that reducing HCQ to this threshold did not affect clinical outcomes in Puerto Rican patients with systemic lupus erythematosus (SLE) after 2 years. To evaluate longer term effects, we extended follow-up to 6 years post-HCQ dose adjustment.
methodsWe conducted a retrospective study on a cohort of Puerto Rican SLE patients whose HCQ doses were adjusted to ≤5.0 mg/kg/day. Disease activity (per-Systemic Lupus Erythematosus Disease Activity Index), lupus exacerbations, hospitalisations, disease damage (per SLICC/ACR Damage Index) and pharmacologic treatments were assessed. Outcomes during the 4-year extension were compared with preadjustment and initial 2-year postadjustment periods. A control group of SLE patients who did not require HCQ dose adjustment was also included.
resultsAmong the 304 patients included in the study, 60 required HCQ dose adjustment, whereas 244 patients did not require modification of their HCQ regimen and served as controls. During the 4-year extension period, a small but statistically significant increase in disease damage was observed in patients who underwent HCQ dose adjustment compared with earlier follow-up periods. Tacrolimus exposure significantly increased, whereas other immunosuppressive therapies remained stable. No increase in disease activity, lupus exacerbations or hospitalisations was observed. Clinical features were comparable between patients who underwent HCQ dose adjustment and those who did not, although patients in the adjusted-dose group had lower weight-based daily HCQ dosing and were less likely to develop HCQ-induced retinopathy.
conclusionsIn this cohort, reducing HCQ to ≤5.0 mg/kg/day was associated with a slight increase in long-term disease damage. No adverse outcomes on disease activity, exacerbations or hospitalisations were observed, supporting the long-term safety of HCQ dose adjustment in Puerto Rican SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.